HomeAI · summaries
Storia in 7 fonti
It's unanimous: SCOTUS agrees with Hikma in 'skinny label' case vs. Amarin
With a resounding unanimous vote, the U.S. | With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma Pharmaceuticals, ruling that its generic version of Amarin’s fish oil-derived cardiovascular drug Vascepa does not infringe patents held by the Irish company.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
washingtonexaminer.com
Treatment for millions at stake in 'skinny label' Supreme Court case
The Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. ruling could have a major effect on incentives to invest in research for FDA‑approved medicines.
- ·
medpagetoday.com
Supreme Court Backs Maker of Generic Heart Drug in 'Skinny Label' Case
Court says defendant Amarin Pharma hasn't shown enough harm; remands case to lower court
- ·
endpoints.news
Supreme Court sides with Hikma in 'skinny label' case
The Supreme Court has unanimously sided with Hikma Pharmaceuticals and its “skinny label” version of a prescription-strength fish oil pill in a case that was closely watched by…
- ·
irishtimes.com
US supreme court backs generic drugmaker over Irish-American firm in patent case
Dublin-based Amarin loses appeal over patent on its cardiovascular drug Vascepa
- ·
statnews.com
Supreme Court backs generic drugmaker in 'skinny labeling' case
The Supreme Court unanimously ruled that Hikma Pharmaceutical did not infringe patents held by Amarin in a decision with implications for lawsuits over so-called skinny labels.
- ·
fiercepharma.com
It's unanimous: SCOTUS agrees with Hikma in 'skinny label' case vs. Amarin
With a resounding unanimous vote, the U.S. | With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma Pharmaceuticals, ruling that its generic version of…
- ·
biopharmadive.com
Generic drugmakers gain key victory in ‘skinny label’ patent case
The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.